ClinicalTrials.gg
RecruitingNCT07729982OPA-LONGUpdated Jul 28, 2026

A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy

An observational study in OPA1 Gene Mutation and Optic Atrophy, Autosomal Dominant, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Ludwig-Maximilians - University of Munich · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

This prospective, monocenter, non-interventional observational study investigates the natural history as well as the clinical and genetic spectrum of OPA1-associated autosomal dominant optic atrophy. Participants will undergo standardized ophthalmic and functional assessments, including visual acuity testing, visual field testing, color vision and contrast sensitivity testing, optical coherence tomography, retinal flavoprotein fluorescence imaging, and video-oculography-based ocular motor and pupillary measurements. The study aims to characterize disease severity and progression over time and to identify structural, metabolic, and functional biomarkers that may serve as clinical endpoints for future therapeutic studies.

02

Conditions studied

  • OPA1 Gene Mutation
  • Optic Atrophy, Autosomal Dominant
03

In context

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from the inherited retinal disease and ophthalmogenetics clinic of the Department of Ophthalmology, University Hospital, Ludwig-Maximilians-Universität München, Germany. The study population consists of patients followed at this tertiary referral center. Additional participants may be referred by genetic diagnostic centers or other physicians in Germany or abroad after molecular genetic testing and clinical suspicion of OPA1-related disease. Self-referral by patients with a previous diagnosis of OPA1-associated autosomal dominant optic atrophy is also accepted.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 years or older
  • Clinical diagnosis or clinical features consistent with optic atrophy
  • Molecular genetic confirmation of a pathogenic or likely pathogenic variant in the OPA1 gene
  • Ability of the participant, or the participant's parent or legal guardian, to understand the nature of the study and provide written

(Participants are eligible for inclusion if all of the criteria mentioned above are met)

Exclusion criteria

Exclusion Criteria:

- Severe systemic disease or medical condition that, in the opinion of the investigator, would preclude participation in the study-related examinations

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in 2.5% low-contrast visual acuity measured with Sloan letter charts

    Change from baseline in low-contrast visual acuity measured using 2.5% low-contrast Sloan letter charts. Low-contrast visual acuity will be recorded as the number of Sloan letters correctly read and may be converted to logMAR for analysis. The unit of measure is number of Sloan letters correctly read.

    Time frame: Baseline and follow-up visits up to 3 years

  2. Change in contrast sensitivity

    Change from baseline in contrast sensitivity measured using the Manifold® Platform from Adaptive Sensory Technology. The unit of measure is log contrast sensitivity.

    Time frame: Baseline and follow-up visits up to 3 years

  3. Change in macular ganglion cell layer thickness measured by optical coherence tomography

    Change from baseline in macular ganglion cell layer thickness, or ganglion cell-inner plexiform layer thickness where applicable, measured by optical coherence tomography. The unit of measure is micrometers.

    Time frame: Baseline and follow-up visits up to 3 years

  4. Change in peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography

    Change from baseline in peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography. The unit of measure is micrometers.

    Time frame: Baseline and follow-up visits up to 3 years

Secondary outcomes

  1. Change in retinal flavoprotein fluorescence intensity measured by flavoprotein fluorescence imaging

    Change from baseline in retinal autofluorescence intensity measured using the OcuMet Beacon confocal scanning ophthalmoscope. The unit of measure is a device-specific autofluorescence intensity score.

    Time frame: Baseline and follow-up visits up to 3 years

  2. Change in central visual field sensitivity measured by Humphrey 10-2 automated perimetry

    Change from baseline in central visual field sensitivity measured using Humphrey 10-2 automated perimetry. The unit of measure is decibels.

    Time frame: Baseline and follow-up visits up to 3 years

  3. Change in protan and tritan colour contrast thresholds measured by the Arden Colour Contrast Test

    Change from baseline in protan and tritan colour contrast thresholds measured using the Arden Colour Contrast Test. Protan and tritan thresholds will be reported separately. The unit of measure is percent contrast.

    Time frame: Baseline and follow-up visits up to 3 years

  4. Change in best-corrected visual acuity (BCVA) measured with high-contrast visual acuity testing

    Change from baseline in best-corrected visual acuity (BCVA) measured using standardized high-contrast visual acuity testing. BCVA will be recorded as the number of letters correctly read or converted to logMAR for analysis. The unit of measure is logMAR or number of letters correctly read.

    Time frame: Baseline and follow-up visits up to 3 years

Other outcomes

  1. Change in pupil diameter measured by video-oculography using BulbiCAM

    Change from baseline in pupil diameter measured by video-oculography using the BulbiCAM Pupil Dynamics test. The unit of measure is millimeters.

    Time frame: Baseline and follow-up visits up to 3 years

  2. Change in pupillary peak velocity measured by video-oculography using BulbiCAM

    Change from baseline in pupillary peak constriction and dilation velocity measured by video-oculography using the BulbiCAM Pupil Dynamics test. Constriction and dilation velocity will be reported separately. The unit of measure is millimeters per second.

    Time frame: Baseline and follow-up visits up to 3 years

  3. Change in cumulative fixation time measured by BulbiCAM Fixation test

    Change from baseline in the cumulative fixation time measured using the BulbiCAM. The unit of measure is seconds.

    Time frame: Baseline and follow-up visits up to 3 years

  4. Change in smooth pursuit gain measured by video-oculography using BulbiCAM

    Change from baseline in device-derived smooth pursuit gain measured during the BulbiCAM Smooth Pursuit test. The unit of measure is percent.

    Time frame: Baseline and follow-up visits up to 3 years

  5. Change in objective central visual field sensitivity measured by KONAN ObjectiveFIELD Analyzer

    Change from baseline in objective central visual field sensitivity measured using the KONAN ObjectiveFIELD Analyzer with multifocal pupillographic objective perimetry. The unit of measure is decibels.

    Time frame: Baseline and follow-up visits up to 3 years

07

Study locations

1 of 1 sites recruiting
  • Department of Ophthalmology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München
    Munich, Bavaria 80336, Germany
    Recruiting
    • Sarah Marxsen · Contactsarah.marxsen@med.uni-muenchen.de · +49-89-4400-53770
    • Claudia Priglinger, Prof. Dr. med. · Sub investigator
    • Günther Rudolph, Prof. Dr. med. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Oct 2030, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2026
First posted
Jul 28, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Oct 2030
CompletionEst.
Nov 2030
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07729982
Responsible party
Maximilian-Joachim Gerhardt (Dr. med., LMU Klinikum) — Principal investigator
First posted
Jul 28, 2026
Start date
Jul 16, 2026
Primary completion
Oct 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Jul 28, 2026

Study contacts

Sarah Marxsen
Contact
sarah.marxsen@med.uni-muenchen.de
+49 89 4400 53770
Ursula Reinstein, Dr. med. vet.
Contact
ursula.reinstein@med.uni-muenchen.de
Maximilian-Joachim Gerhardt, Dr. med.
principal investigator · Department of Ophthalmology, LMU University Hospital, Ludwig-Maximilians-Universität München

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion